Provigil data

Patients in the multicenter, double-blind, randomized, placebo-controlled study received either once-daily doses of placebo, 200 or 400 mg of Provigil for nine weeks, followed by two weeks of observation. According to the MWT, a daytime test of a person's ability to stay awake, patients who received either dose of Provigil stayed awake about 50 percent longer than those on placebo (p<0.001).

The CGI-C, a seven-point scale used to evaluate changes in overall disease status, showed that 60 percent of patients who received 400 mg of drug improved (p<0.001), and 57 percent of those on 200 mg also improved (p<0.001), compared to 37 percent of those on placebo. ...